Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies
Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, Paris M, Teng L, Wollenhaupt J (2017)
Publication Type: Conference contribution
Publication year: 2017
Journal
Book Volume: 69
Authors with CRIS profile
Involved external institutions
Celgene Corporation
United States (USA) (US)
Monash University
Australia (AU)
Swedish Medical Center
United States (USA) (US)
Complejo Hospitalario Universitario de Santiago de Compostela
Spain (ES)
University of Orléans / Université d'Orléans
France (FR)
University of Toronto
Canada (CA)
Schön Klinik Hamburg Eilbek
Germany (DE)
University of California, San Diego
United States (USA) (US)
United States (USA) (US)
Monash University
Australia (AU)
Swedish Medical Center
United States (USA) (US)
Complejo Hospitalario Universitario de Santiago de Compostela
Spain (ES)
University of Orléans / Université d'Orléans
France (FR)
University of Toronto
Canada (CA)
Schön Klinik Hamburg Eilbek
Germany (DE)
University of California, San Diego
United States (USA) (US)
How to cite
APA:
Mease, P.J., Gladman, D.D., Gomez-Reino, J.J., Hall, S., Kavanaugh, A., Lespessailles, E.,... Wollenhaupt, J. (2017). Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies.
MLA:
Mease, Philip J., et al. "Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies." 2017.
BibTeX: Download